14 Result(s)

Article

Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy

Monoclonal IgM anti-myelin-associated glycoprotein (MAG) antibody-related peripheral neuropathy (anti-MAG neuropathy) is predominantly a demyelinating sensory neuropathy with ataxia and distal paresthesia. The...

M. Baron, P. Lozeron, S. Harel, D. Bengoufa, M. Vignon, B. Asli… in Journal of Neurology (2017)

Article

Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients

We retrospectively reviewed 49 patients with light chain (LC) Fanconi syndrome (FS). Patients presented with chronic kidney disease (median estimated glomerular filtration rate (eGFR) of 33 ml/min/1.73 m²) and tu...

M Vignon, V Javaugue, M P Alexander, K El-Karoui, A Karras, D Roos-Weil… in Leukemia (2017)

Article

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, M L Chrétien, B Arnulf… in Leukemia (2013)

Article

Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy

We retrospectively studied a series of 23 patients (median age 50 years, range 29–59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous–allogeneic tandem approach. Tandem tr...

L Karlin, B Arnulf, S Chevret, L Ades, M Robin… in Bone Marrow Transplantation (2011)

Article

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily pretreated patients with relapsed or refractory m...

H Avet-Loiseau, J Soulier, J-P Fermand, I Yakoub-Agha, M Attal, C Hulin… in Leukemia (2010)

Article

Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations

Cryopreservation and thawing of haematopoietic stem cells are associated with cell loss and infusion-related toxicities. We analysed viability, total nucleated cell (TNC) and CD34+ cell recovery, and infusion-...

E Foïs, M Desmartin, S Benhamida, F Xavier, V Vanneaux… in Bone Marrow Transplantation (2007)

Article

Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma

Multiple myeloma (MM) is a B-cell neoplasia caused by the proliferation of clonal plasma cells, primarily in the bone marrow (BM). The role of the BM microenvironment in the pathogenesis of the disease has bee...

B Arnulf, S Lecourt, J Soulier, B Ternaux, M-Noelle Lacassagne, A Crinquette… in Leukemia (2007)

Article

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients

Fludarabine (FDR) therapy gives a response rate of about 30% in previously treated patients with Waldenström's macroglobulinemia (WM). The combination of FDR and cyclophosphamide (Cy) has been shown to be effe...

J Tamburini, V Lévy, C Chaleteix, J P Fermand, A Delmer, L Stalniewicz, P Morel… in Leukemia (2005)

Chapter

Amyloidosis: Round Table

During this round table we should discuss the best choice of treatment of amyloidosis at the present time, and we should try to defiine future perspectives. If we consider treating patients with conventional c...

J. P. Fermand, A. Jaccard, O. Hermine in Monoclonal Gammopathies and the Kidney (2003)

Chapter

New therapeutic approaches for the myeloma patient with and without renal failure

Multiple myeloma (MM) remains a universally fatal malignancy and limited advances in its treatment have been made since the introduction, in the early 1960s, of alkylating agents. Median survival time from dia...

J. P. Fermand in Monoclonal Gammopathies and the Kidney (2003)

Article

Evaluating high dose therapy in Multiple Myeloma: Use of quality-adjusted survival analysis

Purpose: To incorporate quality-of-life considerations in assessing high dose therapy (HDT) for patients with Multiple Myeloma (MM). Patients and methods: A quality-adjusted survival analysis, using the quality-...

R. Porcher, V. Lévy, J.P. Fermand, S. Katsahian, S. Chevret… in Quality of Life Research (2002)

Article

Changing use of intensive care for hematological patients:

Objective: Intensivists generally view patients with hematological malignancies as poor candidates for intensive care. Nevertheless, hematologists have recently developed more aggressive treatment protocols capab...

E. Azoulay, C. Recher, C. Alberti, L. Soufir, G. Leleu… in Intensive Care Medicine (1999)

Chapter

High Dose Chemotherapy and Blood Stem Cell Autologous Graft in Multiple Myeloma

Limited progress in the treatment of multiple myeloma (MM) has been obtained since the introduction of melphalan more than 20 years ago.Response rates to conventional therapy are only in the order of 50% and m...

J. P. Fermand, Y. Levy, M. Adam, X. Sithy, J. M. Miclea… in Advances in haemapheresis (1991)